Prognosis and severity of myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related diseases | Zendy

Nakashima Ichiro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Prognosis and severity of myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related diseases

Author(s) -

Nakashima Ichiro

Publication year - 2017

Publication title -

clinical and experimental neuroimmunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.297

H-Index - 15

ISSN - 1759-1961

DOI - 10.1111/cen3.12385

Subject(s) - myelin oligodendrocyte glycoprotein , neuromyelitis optica , multiple sclerosis , oligodendrocyte , demyelinating disease , myelin , antibody , immunology , demyelinating disorder , medicine , myelin associated glycoprotein , glycoprotein , immunoglobulin g , spectrum disorder , biology , central nervous system , microbiology and biotechnology , experimental autoimmune encephalomyelitis , psychiatry

Myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related demyelinating disease is part of a relatively new disease spectrum that differs from multiple sclerosis. A recent European study showed that adult onset myelin oligodendrocyte glycoprotein‐immunoglobulin G‐related demyelinating disease might have frequent relapses and a poor prognosis similar to anti‐aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorders.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research